Tong Wu Yujun Li Xiaonan Cui Chunxia Zhang
10.3389/fimmu.2023.1243980
Front Immunol
2023 Aug 15;14:1243980.
pd-l1 inhibitor cardiotoxicity case report squamous nsclc sugemalimab tislelizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/37649479/
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Squamous Cell / drug therapy Lung Neoplasms / drug therapy
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Squamous Cell / drug therapy Lung Neoplasms / drug therapy Case Reports Cardiotoxicity Humans Immune Checkpoint Inhibitors / adverse effects Immune Checkpoint Inhibitors sugemalimab
PMC10465174
37649479
Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
2023